Newsletter

Is Drug Repurposing the new breakthrough for faster approval of Psychedelic-assisted treatments? In this TDR Psychedelic Exclusive, we speak with the CEO of Algernon Pharmaceuticals (CNSX: AGN) (OTC: AGNPF) Christopher Moreau who explains the company’s recent...

CEO Christopher J. Moreau provides an update on Algernon Pharmaceuticals Inc. announcement that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188...

Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or...

  “Drug Could Possibly Both Reduce Acute Damage of the Stroke” - How DMT Could be the Future of Stroke Treatment     Dr Rick Strassman, one of the most well-known researchers and authors on DMT, shares with SR Times his expert knowledge on using DMT as...

CEO Christopher J. Moreau provides an update on the Company's Ifendprodil drug program targeting chronic cough. The Company is planning a phase 2b study for later this year. About Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals is a Canadian clinical stage drug...

Algernon Pharmaceuticals CEO Christopher J. Moreau provides update on AP-188 DMT (Dimethyltryptamine) Stroke Program. Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study https://www.globenewswire.com/news-re... About Algernon NeuroScience...